The TRT lab panel is not one number. It is a system: total T, free T, SHBG, LH, FSH, estradiol (sensitive assay), hematocrit, hemoglobin, IGF-1, PSA. Each marker answers a different question. Pulled in the wrong window, half of them lie.
What each marker is actually measuring
Total testosterone is the sum of three pools: testosterone bound to SHBG (tightly, biologically inert), testosterone bound to albumin (loosely, partially bioavailable), and free testosterone (unbound, the only fraction that crosses cell membranes and binds androgen receptors). The practitioner consensus is unambiguous on this: total T on TRT does not matter in isolation. What matters is whether the free fraction is high enough to drive androgen-receptor activity at the tissue.
SHBG (sex hormone-binding globulin) is the gatekeeper. It is a liver-made protein that binds testosterone in circulation and renders it inactive. High SHBG means most of your total T is sequestered — you can look replete on paper and be symptomatic. Low SHBG means more of your total T is free, but it also means the half-life is shorter and the swings are sharper. The practitioner pattern: if SHBG is high, you push total T higher to liberate more free T. If SHBG is low, you do not need a high total — you may need to throttle injection frequency up (daily or EOD instead of twice weekly) to stabilize the curve. The one reason to actively preserve SHBG is fertility — men trying to conceive keep SHBG on because of how it modulates the gonadal axis.
Free testosterone is the number that correlates with how you feel. The bioavailable fraction (free + albumin-bound) is the second-best proxy. Track these, not total, as the primary efficacy signal once you are stable on protocol.
LH and FSH are the upstream pituitary signals. On exogenous testosterone, both should suppress to near-zero — that is the expected pharmacology, not a complication. They become signal again only when you are off-cycle, on HCG or Gonadorelin to preserve testicular function, or running a restart protocol. If LH and FSH are not suppressed on TRT, the dose is too low to register at the hypothalamus, or there is an assay issue.
Estradiol (sensitive assay only) is the marker most clinics get wrong. Standard estradiol assays are calibrated for women and read garbage at the male physiological range. You need the LC-MS/MS sensitive assay. The practitioner-consensus optimal range for men on TRT is 20–35 pg/mL, with concern at >50 pg/mL. The mistake almost everyone makes: crashing E2 with anastrozole because the number looks high. Men require higher estradiol on therapeutic testosterone than the female-calibrated reference range suggests. Crashed E2 produces joint pain, depressed mood, lipid derangement, and bone-density loss. The corpus is consistent: do not crash estrogen. If aromatization is genuinely excessive, low-dose anastrozole (0.25–0.5 mg, 2x/week, titrated) is the lever — not a sledgehammer.
Hematocrit and hemoglobin are the safety marker. Injectable testosterone reliably raises red-cell mass. Some elevation is beneficial — more oxygen-carrying capacity. Sustained hematocrit above ~54% is the threshold where stroke and clotting risk become real. The practitioner protocol: monitor every 3 months on TRT, and if hematocrit climbs, reduce dose first before phlebotomy. Phlebotomy works but it crashes iron, and crashed iron has its own downstream consequences (fatigue, hair loss, thyroid impairment).
IGF-1 is your growth-hormone-axis baseline and an important lateral marker on TRT. GH and testosterone interact. If you ever layer a GH secretagogue (CJC/Ipamorelin, Tesamorelin, MK-677) on top of TRT, you need a pre-stack IGF-1 to interpret the response.
PSA is the prostate safety marker, and the practitioner posture has shifted. A single PSA value tells you very little. PSA velocity — the trend over 12–18 months — is the signal. A sustained rise of >0.35 ng/mL/year over baseline is the threshold that warrants workup. Baseline most men on TRT will sit under 4 ng/mL. If you are on finasteride or dutasteride, your PSA reading is artificially suppressed (roughly halved) and your clinician must adjust interpretation accordingly.
Timing — when to pull, and why it matters
| Marker | Timing Window | Frequency | Evidence Tier |
|---|---|---|---|
| Total T, Free T, SHBG | Trough — day of next injection, before injecting | Baseline, 8 weeks post-start, then every 6 months | 🟢 Expert |
| LH, FSH | Baseline (pre-TRT) and during restart protocols | Once at baseline; not routine on TRT | 🟢 Expert |
| Estradiol (sensitive assay, LC-MS/MS) | Trough, same draw as testosterone | Baseline, 8 weeks, then every 6 months | 🟢 Expert |
| Hematocrit, Hemoglobin (CBC) | Any time; less sensitive to timing | Baseline, 8 weeks, then every 3 months | 🟢 Expert |
| IGF-1 | Morning, fasted | Baseline; repeat if adding GH secretagogue | 🟢 Expert |
| PSA | Any time, but consistent (morning preferred) | Baseline, annually; track velocity over years | 🔵 Clinical |
| Lipid panel, fasting glucose, fasting insulin, CRP | Morning, fasted | Baseline and every 6 months | 🔵 Clinical |
| CMP (liver, kidney, electrolytes) | Morning, fasted | Baseline and every 6 months | 🔵 Clinical |
The trough rule is the one most men get wrong. Drawing testosterone the morning after an injection gives you a peak value that has no clinical meaning. The corpus is consistent: draw at trough — the day of your next scheduled injection, before injecting. That is the floor your protocol is holding. If trough is in target, peak is taking care of itself.
The 8-week recheck is the abbreviated panel — total T, free T, SHBG, sensitive estradiol, hematocrit. Not the full Tier-1 workup. This is the protocol-adjustment draw, not the safety draw. You are checking that the injection frequency and dose are landing where you want them. The full panel re-runs at 6 months.
Lagging vs. leading indicators
Hematocrit is the leading safety indicator on TRT — it moves before symptoms appear. Watch it.
Estradiol is leading for sexual function, mood, and joint comfort. Crashed E2 hurts in days, not weeks.
Total T and free T are lagging — they reflect what your protocol has been doing for the last 4–6 weeks. Adjusting dose based on a single trough reading inside an 8-week window is overcorrection.
PSA is deeply lagging — multi-year trends, not snapshots. One elevated reading is not actionable; sustained velocity is.
Fasting insulin is leading for the metabolic-axis interaction. If insulin starts climbing on TRT, GH secretagogues are off the table until it is corrected — GH secretagogues into insulin resistance is the wrong direction.
What's NOT happening yet
- LH and FSH are not "broken" because they read near zero on TRT. That is the expected pharmacology of exogenous androgen suppression. Restoring them requires a different protocol (HCG, Gonadorelin, or a cessation restart).
- Estradiol at 38 pg/mL on a sensitive assay is not "high estrogen." It is a normal therapeutic-testosterone range for men. The instinct to crash it with anastrozole is the most common iatrogenic injury in TRT.
- A single PSA tick from 1.1 to 1.4 ng/mL is not prostate cancer. It is noise inside the assay window. Velocity over 12+ months is the signal.
- Total testosterone hitting 1,200 ng/dL is not the win condition. If free T and symptoms are not where you want them at 800 ng/dL total with normal SHBG, pushing total higher is not the lever — injection frequency, SHBG modulation, or estradiol management is.
- The reference ranges on your lab printout are population ranges, weighted by sick people. Optimal is not the middle of the range. Optimal is symptom-driven, anchored to free T and bioavailable T, cross-referenced against E2, hematocrit, and how you actually feel.
Symptoms trump lab numbers — but the labs tell you which lever to pull. Track them. Adjust.